Drugs / SS1P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00006981 | Dec 2000 → ? | cervical cancer, fallopian tube cancer, head and neck cancer, lung cancer +4 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SS1P | “PURPOSE: To conduct a phase I trial of recombinant immunotoxin SS1P given by continuous infusion in chemoresistant solid tumors expressing mesothelin.” PMID 19671873 ↗ Aug 2009 |
| Modality | Protein / enzyme biologic | “recombinant immunotoxin SS1P” PMID 19671873 ↗ Aug 2009 |
| Route | Intravenous | “Patients receive SS1(dsFv)-PE38 immunotoxin IV continuously on days 1-10.” NCT00006981 ↗ |